vs
Alpha Metallurgical Resources, Inc.（AMR）与EXACT SCIENCES CORP（EXAS）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Alpha Metallurgical Resources, Inc.的1.7倍（$878.4M vs $519.1M），Alpha Metallurgical Resources, Inc.净利率更高（-3.3% vs -9.8%，领先6.5%），EXACT SCIENCES CORP同比增速更快（23.1% vs -15.7%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $-10.0M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -22.4%）
阿尔法冶金资源（前身为康图拉能源）是行业领先的煤炭供应商，在阿巴拉契亚北部和中部拥有地下及露天煤矿综合体，在宾夕法尼亚州、弗吉尼亚州和西弗吉尼亚州坐拥大型煤田，生产用于炼钢的冶金煤和用于发电的动力煤，供应全球下游客户。
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
AMR vs EXAS — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $519.1M | $878.4M |
| 净利润 | $-17.3M | $-86.0M |
| 毛利率 | — | 70.1% |
| 营业利润率 | -4.1% | -9.4% |
| 净利率 | -3.3% | -9.8% |
| 营收同比 | -15.7% | 23.1% |
| 净利润同比 | -711.2% | 90.1% |
| 每股收益（稀释后） | $-1.35 | $-0.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $519.1M | $878.4M | ||
| Q3 25 | $525.2M | $850.7M | ||
| Q2 25 | $548.7M | $811.1M | ||
| Q1 25 | $529.7M | $706.8M | ||
| Q4 24 | $615.4M | $713.4M | ||
| Q3 24 | $669.8M | $708.7M | ||
| Q2 24 | $800.1M | $699.3M | ||
| Q1 24 | $861.3M | $637.5M |
| Q4 25 | $-17.3M | $-86.0M | ||
| Q3 25 | $-5.5M | $-19.6M | ||
| Q2 25 | $-5.0M | $-1.2M | ||
| Q1 25 | $-33.9M | $-101.2M | ||
| Q4 24 | $-2.1M | $-864.6M | ||
| Q3 24 | $3.8M | $-38.2M | ||
| Q2 24 | $58.9M | $-15.8M | ||
| Q1 24 | $127.0M | $-110.2M |
| Q4 25 | — | 70.1% | ||
| Q3 25 | — | 68.6% | ||
| Q2 25 | — | 69.3% | ||
| Q1 25 | — | 70.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 69.4% | ||
| Q2 24 | — | 69.8% | ||
| Q1 24 | — | 70.0% |
| Q4 25 | -4.1% | -9.4% | ||
| Q3 25 | -0.5% | -3.0% | ||
| Q2 25 | 0.5% | -0.3% | ||
| Q1 25 | -7.6% | -13.6% | ||
| Q4 24 | 1.6% | -122.8% | ||
| Q3 24 | 0.8% | -5.6% | ||
| Q2 24 | 8.8% | -3.8% | ||
| Q1 24 | 16.5% | -16.7% |
| Q4 25 | -3.3% | -9.8% | ||
| Q3 25 | -1.1% | -2.3% | ||
| Q2 25 | -0.9% | -0.1% | ||
| Q1 25 | -6.4% | -14.3% | ||
| Q4 24 | -0.3% | -121.2% | ||
| Q3 24 | 0.6% | -5.4% | ||
| Q2 24 | 7.4% | -2.3% | ||
| Q1 24 | 14.7% | -17.3% |
| Q4 25 | $-1.35 | $-0.45 | ||
| Q3 25 | $-0.42 | $-0.10 | ||
| Q2 25 | $-0.38 | $-0.01 | ||
| Q1 25 | $-2.60 | $-0.54 | ||
| Q4 24 | $-0.09 | $-4.69 | ||
| Q3 24 | $0.29 | $-0.21 | ||
| Q2 24 | $4.49 | $-0.09 | ||
| Q1 24 | $9.59 | $-0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $415.6M | $964.7M |
| 总债务越低越好 | $9.8M | — |
| 股东权益账面价值 | $1.5B | $2.4B |
| 总资产 | $2.3B | $5.9B |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
| Q4 25 | $415.6M | $964.7M | ||
| Q3 25 | $457.9M | $1.0B | ||
| Q2 25 | $449.0M | $858.4M | ||
| Q1 25 | $448.0M | $786.2M | ||
| Q4 24 | $481.6M | $1.0B | ||
| Q3 24 | $484.6M | $1.0B | ||
| Q2 24 | $336.1M | $946.8M | ||
| Q1 24 | $269.4M | $652.1M |
| Q4 25 | $9.8M | — | ||
| Q3 25 | $2.9M | — | ||
| Q2 25 | $3.1M | — | ||
| Q1 25 | $2.4M | — | ||
| Q4 24 | $2.9M | — | ||
| Q3 24 | $3.6M | — | ||
| Q2 24 | $5.3M | — | ||
| Q1 24 | $6.0M | — |
| Q4 25 | $1.5B | $2.4B | ||
| Q3 25 | $1.6B | $2.5B | ||
| Q2 25 | $1.6B | $2.5B | ||
| Q1 25 | $1.6B | $2.4B | ||
| Q4 24 | $1.6B | $2.4B | ||
| Q3 24 | $1.7B | $3.2B | ||
| Q2 24 | $1.6B | $3.2B | ||
| Q1 24 | $1.6B | $3.1B |
| Q4 25 | $2.3B | $5.9B | ||
| Q3 25 | $2.3B | $5.9B | ||
| Q2 25 | $2.4B | $5.8B | ||
| Q1 25 | $2.4B | $5.7B | ||
| Q4 24 | $2.4B | $5.9B | ||
| Q3 24 | $2.5B | $6.7B | ||
| Q2 24 | $2.5B | $6.7B | ||
| Q1 24 | $2.5B | $6.4B |
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.0M | $151.7M |
| 自由现金流经营现金流 - 资本支出 | $-10.0M | $120.4M |
| 自由现金流率自由现金流/营收 | -1.9% | 13.7% |
| 资本支出强度资本支出/营收 | 5.6% | 3.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $17.8M | $356.8M |
8季度趋势，按日历期对齐
| Q4 25 | $19.0M | $151.7M | ||
| Q3 25 | $50.5M | $219.9M | ||
| Q2 25 | $53.2M | $89.0M | ||
| Q1 25 | $22.2M | $30.8M | ||
| Q4 24 | $56.3M | $47.1M | ||
| Q3 24 | $189.5M | $138.7M | ||
| Q2 24 | $138.1M | $107.1M | ||
| Q1 24 | $196.1M | $-82.3M |
| Q4 25 | $-10.0M | $120.4M | ||
| Q3 25 | $25.4M | $190.0M | ||
| Q2 25 | $18.6M | $46.7M | ||
| Q1 25 | $-16.3M | $-365.0K | ||
| Q4 24 | $13.6M | $10.7M | ||
| Q3 24 | $158.0M | $112.6M | ||
| Q2 24 | $77.0M | $71.2M | ||
| Q1 24 | $132.5M | $-120.0M |
| Q4 25 | -1.9% | 13.7% | ||
| Q3 25 | 4.8% | 22.3% | ||
| Q2 25 | 3.4% | 5.8% | ||
| Q1 25 | -3.1% | -0.1% | ||
| Q4 24 | 2.2% | 1.5% | ||
| Q3 24 | 23.6% | 15.9% | ||
| Q2 24 | 9.6% | 10.2% | ||
| Q1 24 | 15.4% | -18.8% |
| Q4 25 | 5.6% | 3.6% | ||
| Q3 25 | 4.8% | 3.5% | ||
| Q2 25 | 6.3% | 5.2% | ||
| Q1 25 | 7.3% | 4.4% | ||
| Q4 24 | 6.9% | 5.1% | ||
| Q3 24 | 4.7% | 3.7% | ||
| Q2 24 | 7.6% | 5.1% | ||
| Q1 24 | 7.4% | 5.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 49.81× | — | ||
| Q2 24 | 2.34× | — | ||
| Q1 24 | 1.54× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMR
暂无分部数据
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
